Novocure Ltd

NovoCure has raised its 2026 net revenue guidance to a range of US$710 million to US$725 million following a quarter of record sales and active patient growth. The stock has gained 41.54% over the past three months and 46.59% over one year, though longer-term total shareholder returns over three and five years remain significantly negative. The most followed fair value estimate among investors stands at $26.07 per share, well above the last close of $17.65, implying the stock is undervalued. Validation of TTFields therapy in new indications such as pancreatic cancer and brain metastases from non-small cell lung cancer positions the company for potential regulatory approvals and market expansion beginning in 2026.

Advanced Biomed shares rallied as much as 211% this week, leading a group of biotech gainers that also included Novocure, Medpace, and others. Advanced Biomed, which has not yet commenced commercial sales, soared from $6.71 to an intraday high of $20.87 before closing Thursday at $16.78, up 36.98% on the day. Novocure surged more than 28% after reporting second-quarter total net revenues of $183.6 million, a 16% year-over-year increase, and raising its full-year 2026 revenue guidance to $710 million to $725 million from a prior range of $690 million to $710 million. Medpace gained more than 14% following second-quarter revenue of $707.3 million, up 17.2% from the prior-year period, and a full-year 2026 revenue forecast of $2.805 billion to $2.885 billion. Other notable movers included SciSparc, up over 20% on no specific news, Agenus, up more than 11% after announcing an oversubscribed private placement of up to $340 million, and AgomAb Therapeutics, up more than 11% ahead of expected clinical data readouts.

Novocure Ltd shares surged to a new 52-week high on Thursday after the company raised its full-year 2026 revenue guidance and investors anticipated premarket approval for its brain therapy candidate. The stock reached an intraday record of $20.55 before closing up 28.39 percent at $19.99. Novocure lifted its revenue growth forecast to a range of $710 million to $725 million, up from $690 million to $710 million previously, and now expects positive adjusted EBITDA of up to $15 million, reversing an earlier loss outlook. The improved guidance followed second-quarter revenues of $183.6 million, a 16 percent increase from the prior year, while net loss narrowed 61 percent to $15.6 million. The company is awaiting FDA premarket approval in the fourth quarter for its TTFields therapy in patients with brain metastases from non-small cell lung cancer.

NovoCure reported a second-quarter adjusted loss of $0.13 per share, beating the Zacks Consensus Estimate of a $0.30 loss and improving from a loss of $0.36 per share a year ago. Revenue reached $183.58 million, surpassing the consensus by 5.44% and up from $158.8 million in the prior-year quarter. The company has topped consensus EPS estimates three times in the past four quarters and exceeded revenue estimates in all four of those quarters. Shares have gained about 20.4% year to date, outperforming the S&P 500's 9.6% advance.

NovoCure has received the CE mark for its portable medical device Optune Pax for treating adult patients with locally advanced pancreatic cancer of exocrine origin. The non-invasive device is approved in Europe for use concomitantly with gemcitabine and nab-paclitaxel, and the company plans to begin its launch in the coming weeks, starting with Germany. The approval was supported by data from the phase III PANOVA-3 study, which showed a statistically significant 2.0-month improvement in median overall survival in the intent-to-treat population. Optune Pax had already received FDA approval earlier this year, becoming the first treatment approved for locally advanced pancreatic cancer in nearly 30 years. Despite the news, NovoCure shares closed 2.1% lower on the day, though the stock has gained 17.2% year-to-date.

The Motley Fool compared HeartFlow and NovoCure and concluded that NovoCure is the better buy for long-term investors in 2026. HeartFlow, which uses AI for non-invasive coronary artery disease diagnosis, reported fiscal 2025 revenue of approximately $176 million, a 40% increase, but a net loss of $116.8 million. NovoCure, which develops Tumor Treating Fields therapy for cancer, generated about $655.4 million in revenue, up 8.3%, with a net loss of nearly $136.2 million. NovoCure's projected fiscal 2026 revenue of $704 million and lower price-to-sales ratio of 2.5x compared to HeartFlow's 15.5x make it the preferred choice despite both companies not expected to generate positive free cash flow until 2028.